ライフサイエンスコーパス: cryoablation

1 and type of ablation (radiofrequency versus cryoablation).

2 .9 cm) in 12 patients were treated (18 total cryoablations).

3 cally lower than those seen with whole-gland cryoablation.

4 e and associated risk factors for bone tumor cryoablation.

5 ble for laparoscopic partial nephrectomy and cryoablation.

6 chemotherapy were treated with percutaneous cryoablation.

7 orted a reduction in these medications after cryoablation.

8 frequency, laser, microwave, ultrasound, and cryoablation.

9 ion, microwave ablation, laser ablation, and cryoablation.

10 s were excised at lumpectomy 2-3 weeks after cryoablation.

11 may be indicators of likelihood of complete cryoablation.

12 onary vein stenosis appears to be lower with cryoablation.

13 pdate on the safety and efficacy of catheter cryoablation.

14 frequency, laser, microwave, ultrasound, and cryoablation.

15 oventricular block in patients who underwent cryoablation.

16 images can be normal findings after hepatic cryoablation.

17 yonecrosis that were obtained 24 hours after cryoablation.

18 onography (US) were performed 7-8 days after cryoablation.

19 f tissue necrosis is important when planning cryoablation.

20 ndergo PFA, and 105 were assigned to undergo cryoablation.

21 ith other cancer-directed treatment, such as cryoablation.

22 durably treated with CT-guided percutaneous cryoablation.

23 e biopsy that was performed 2-4 weeks before cryoablation.

24 lesions for both radiofrequency ablation and cryoablation.

25 ibrillation in a 1:1 ratio to undergo PFA or cryoablation.

26 to treatment of a single tumor with partial cryoablation.

27 an anti-tumour immune response stimulated by cryoablation.

28 utic procedures: radiofrequency ablation and cryoablation.

29 nd tissue temperatures were monitored during cryoablation.

30 One patient underwent primary cryoablation.

31 with 3 radiofrequency-failures/conversion to cryoablation.

32 r complications in patients undergoing renal cryoablation.

33 n/electroporation, and ultra-low temperature cryoablation.

34 ful retreatment with MR imaging-guided focal cryoablation.

35 elivery are the goals of research in RFA and cryoablation.

36 androgen deprivation monotherapy to 74% for cryoablation.

37 -4 adverse events was 3% (121 of 3726) after cryoablation, 2% (39 of 2503) after radiofrequency ablat

38 ; 35 [53.0%] men) were enrolled and received cryoablation; 65 completed follow-up.

39 ither RF (30 W, 50 degrees C, 60 seconds) or cryoablation (-80 degrees C for 5 minutes).

40 Of the 163 patients randomized to cryoablation, 84 patients experienced ERAF (51.5%).

41 y, in the 22 patients who underwent surgical cryoablation, a single event occurred 7 years after PVR.

42 ved understanding of the mechanisms by which cryoablation affects innate and adaptive immunity will h

43 Cryoablation alone eliminated epicardial posteroseptal a

44 growth of secondary tumors was unaffected by cryoablation alone, the combination treatment was suffic

45 Catheter cryoablation also can be used to isolate the pulmonary v

46 recurrence at 6 months follow-up was 0% for cryoablation and 44% for radiofrequency (P=0.03).

47 d at core biopsy were treated with US-guided cryoablation and a 2.7-mm cryoprobe.

48 to local tumor recurrence even with combined cryoablation and CpG treatment.

49 Cryoablation and high-intensity focused ultrasound of th

50 tion is associated with the thawing phase of cryoablation and may be related to soluble mediator(s) r

51 incomplete cryoablation, and (d) incomplete cryoablation and MMP inhibitor.

52 Data are lacking on long-term outcomes from cryoablation and on the most effective balloon size.

53 Cryoablation and radio frequency ablation are effective

54 iterature demonstrating the effectiveness of cryoablation and radio frequency ablation performed lapa

55 Although the initial outcomes of cryoablation and radiofrequency ablation are encouraging

56 Three- and 4-year data for cryoablation and radiofrequency ablation are now becomin

57 Cryoablation and radiofrequency ablation are the two mos

58 Currently, cryoablation and radiofrequency ablation are the two mos

59 rimental and clinical, on the application of cryoablation and radiofrequency ablation for the treatme

60 Three- and five-year outcomes following cryoablation and radiofrequency ablation have recently b

61 term outcomes of probe-ablative therapy with cryoablation and radiofrequency ablation suggest satisfa

62 Cryoablation and radiofrequency ablation therapies have

63 aterial has yet been identified to test both cryoablation and radiofrequency ablation.

64 nclusion In a mouse model of HCC, incomplete cryoablation and systemic MMP inhibition showed increase

65 iofrequency ablation, microwave ablation, or cryoablation and that reported on local control outcomes

66 of urologic tumors in the form of freezing (cryoablation) and heating (radiofrequency ablation) have

67 treatment, (b) MMP inhibitor, (c) incomplete cryoablation, and (d) incomplete cryoablation and MMP in

68 al-beam radiation, 13.3% brachytherapy, 4.0% cryoablation, and 14.4% androgen deprivation monotherapy

69 r induced thermotherapy, microwave ablation, cryoablation, and extracorporeal high-intensity focused

70 rrent trends towards nerve-sparing and focal cryoablation are also discussed.

71 fibrillation (AF) such as radiofrequency or cryoablation are controversial due to mixed results.

72 te indicate that radiofrequency ablation and cryoablation are effective therapies with acceptable sho

73 dures such as transarterial embolization and cryoablation are leading to a new generation of patients

74 ion, microwave ablation, laser ablation, and cryoablation are reviewed with respect to the various cl

75 Most cryoablations are performed using a laparoscopic approac

76 Thermal therapeutic options, especially cryoablation, are of growing interest for the treatment

77 n Best Practice Guidelines identify prostate cryoablation as both primary and salvage therapies.

78 orted for early rhythm control therapy15 and cryoablation as initial AF treatment.25,26 Subcutaneous

79 Ischemic retina was treated with cryoablation as necessary.

80 rall survival probability after percutaneous cryoablation at 5 years and 10 years was longer than for

81 e success rates were 90% and 77% for RFA and cryoablation at the ideal site, respectively.

82 (A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atr

83 in diameter) were treated with percutaneous cryoablation between December 2020 and December 2023.

84 nal metastasis who were treated with adrenal cryoablation between May 2005 and October 2009 were elig

85 nd lung tissue samples of animals undergoing cryoablation but not after RFA, and serum cytokine level

86 respiratory distress syndrome (ARDS), after cryoablation but not RFA.

87 rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula

88 Hepatic cryoablation, but not RFA, induces NF-kappaB activation

89 Minimally-invasive, parenchyma-preserving cryoablation can be considered as a potential feasible o

90 Clinically, radio frequency ablation and cryoablation can be performed percutaneously or laparosc

91 emperatures to destroy cells; transcutaneous cryoablation can be performed under imaging guidance.

92 If cryoablation can induce a systemic tumor-specific respon

93 Cryoablation can strengthen the tumor response to immuno

94 iority of either radio frequency ablation or cryoablation cannot be confirmed based on available lite

95 Focal ablation was performed using an 8-mm cryoablation catheter or a 4-mm open-irrigated radiofreq

96 Keywords: Cancer, Cryoablation, Checkpoint Inhibitor Immunotherapy, Tumor

97 We also examined the efficacy and safety of cryoablation close to a CA.

98 rstand the mechanism of immune activation by cryoablation, comprehensive analyses of innate immunity

99 on renal radio frequency ablation (RFA) and cryoablation confirming their oncologic efficacy emerge,

100 Some studies indicate that cryoablation could be as effective and safe as lumpectom

101 esponse to radiofrequency ablation (RFA) and cryoablation (CRA) was characterized and compared in a c

102 Intercostal nerve cryoablation (CRYO) performed during the primary surgica

103 Cryoablation destroys tumor tissue by applying extreme c

104 , and in select high-risk patients, surgical cryoablation does not seem to increase arrhythmic events

105 a to select appropriate candidates for focal cryoablation due to the complexity of tumorigenesis in e

106 (79%) drug-treated patients crossed over to cryoablation during 12 months of study follow-up due to

107 0%) had catheter ablation, 3 (2.5%) surgical cryoablation during PVR, and 9 (7.5%) defibrillator impl

108 After cryoablation, EADs from surviving epicardium (~1 mm) fir

109 Patients undergoing adrenal cryoablation experienced a significant increase in systo

110 -term and long-term oncologic outcomes after cryoablation for kidney tumors are satisfactory.

111 MDP) within the prostate bed was found after cryoablation for prostate carcinoma.

112 o review the evolution and current status of cryoablation for renal tumors.

113 sults of the first clinical studies of focal cryoablation for select patients with low volume and low

114 assessed patients who underwent percutaneous cryoablation for solitary pathology-proven cT1 RCC betwe

115 rt our results using argon-based endocardial cryoablation for the treatment of AF in patients undergo

116 atients who underwent percutaneous CT-guided cryoablation for the treatment of osteoid osteoma betwee

117 Purpose To evaluate percutaneous CT-guided cryoablation for the treatment of osteoid osteoma in you

118 R], 19-38 years; 31 men) underwent CT-guided cryoablation for the treatment of osteoid osteoma, with

119 he acute procedural success rate of catheter cryoablation for this arrhythmia may be slightly lower t

120 l specimens obtained after ultrasound-guided cryoablation from patients with HER2-negative luminal br

121 rescence and histologic evaluation following cryoablation further demonstrated a robust CD8 T-cell an

122 s in the PFA group and in 53 patients in the cryoablation group (Kaplan-Meier cumulative incidence, 3

123 No patients in the cryoablation group required any additional or alternate

124 nyl (165.0 microg [RF group] vs 75.0 microg [cryoablation group]; P < .001) and midazolam (2.9 mg [RF

125 and midazolam (2.9 mg [RF group] vs 1.6 mg [cryoablation group]; P = .026).

126 n 23 patients with AT, using inferomedial RA cryoablation (Group 1, n=8) and modified RA maze procedu

127 for systemic inflammation, rats treated with cryoablation had either immediate resection of the ablat

128 Cryoablation has been incorporated into our institution'

129 Background Percutaneous cryoablation has been shown to be effective in the manag

130 Percutaneous cryoablation has good success rates for treating breast

131 Cryoablation has proven effective in the treatment of be

132 RFA and cryoablation have each been used for renal tissue ablati

133 hniques, the clinical safety and efficacy of cryoablation have not been established for osteoid osteo

134 ofrequency ablation, microwave ablation, and cryoablation, have emerged as key treatment options for

135 Methods such as chemical ablation, cryoablation, high-temperature ablation (radiofrequency,

136 ty focused ultrasound, focal laser ablation, cryoablation, hyperthermia, or irreversible electroporat

137 sis was seen on angiography after epicardial cryoablation in 1 patient.

138 ent; transcoronary alcohol in 6 and surgical cryoablation in 2 patients), acute success (noninducibil

139 cy ablation was conducted in 17 patients and cryoablation in 27, with comparable success rates (82% r

140 Cryoablation in combination with immune checkpoint thera

141 the size of the necrotic area after hepatic cryoablation in normal pig liver.

142 melimumab) with (n = 15) or without (n = 14) cryoablation in patients with metastatic renal cell carc

143 irrigated radiofrequency ablation in one and cryoablation in the other) and ablation within the middl

144 ing percutaneous radiofrequency ablation and cryoablation in the treatment of renal cell carcinoma ar

145 Mean blood loss from percutaneous cryoablation in this model was between that for RF ablat

146 ; irreversible electroporation, in five; and cryoablation, in one.

147 Following cryoablation, increases in inflammatory cytokines and ch

148 Image-guided Thermal Ablation, Percutaneous Cryoablation, Intercostal Neuralgia, Cryosurgery, Ablati

149 Percutaneous cryoablation is a minimally invasive procedure for tumor

150 Cryoablation is a percutaneous thermal ablation techniqu

151 Catheter cryoablation is a safe and clinically effective method f

152 For many cardiac arrhythmias, catheter cryoablation is a safe and effective alternative to radi

153 ioventricular block is substantial, catheter cryoablation is a safe and effective alternative to radi

154 Percutaneous cryoablation is a safe and effective method for palliati

155 Cryoablation is a safe and reasonably effective alternat

156 Percutaneous cryoablation is a technically effective treatment approa

157 Cryoablation is a therapeutic technique that uses very l

158 Cryoablation is a well-tolerated outpatient procedure th

159 Cryoablation is an effective and safe procedure and shou

160 Image-guided percutaneous cryoablation is an established minimally invasive oncolo

161 Although cryoablation is currently used to treat a targeted tumor

162 Cryoablation is done on an outpatient basis, avoiding ge

163 CT-monitored percutaneous cryoablation is feasible and safe in this pig liver mode

164 Renal cryoablation is most commonly performed percutaneously o

165 Cryoablation is one of the methods of treating patients

166 Background Cryoablation is playing an increasing role in the percut

167 ancer-specific survival of 98%, laparoscopic cryoablation is safe and can be performed with minimal i

168 Conclusion Bone tumor cryoablation is safe, with a 2.5% rate of major complica

169 Adrenal cryoablation is technically feasible with a high rate of

170 Cryoablation is the most evaluated probe ablative method

171 Renal cryoablation is the most studied of all the energy based

172 radiofrequency ablation, microwave ablation, cryoablation, laser ablation and irreversible electropor

173 tion (RFA), a combination of bipolar RFA and cryoablation, laser therapy and photodynamic therapy.

174 Cryoablation led to a decrease in diffuse reflectance ac

175 orescence for the real-time visualization of cryoablation lesions in blood-perfused cardiac muscle pr

176 ve interventions (hepatic chemoembolization, cryoablation, liver transplantation).

177 With adrenal cryoablation, local control was achieved following treat

178 tilizing bipolar radiofrequency ablation and cryoablation, long-term studies have demonstrated a sign

179 udies suggest that cell disruption caused by cryoablation may increase the expression and immunogenic

180 lthough the acute procedural success rate of cryoablation may not equal that of radiofrequency ablati

181 ted long-term outcomes data assessing recent cryoablation methods.

182 med in larger studies with longer follow-up, cryoablation might constitute a safe and efficacious tec

183 Five normal pig livers were treated with cryoablation monitored with US.

184 the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT), f

185 Results Mice treated with incomplete cryoablation (n = 6) showed greater infiltration of CD20

186 ned to receive pulmonary vein isolation with cryoablation (n = 64) or a sham procedure with phrenic n

187 iod, 10 men (mean age, 66.5 years) underwent cryoablation of 11 renal lesions, and 14 patients (11 me

188 severe complication associated with hepatic cryoablation of 30% to 35% or more of liver parenchyma,

189 years; age range, 6-86 years) who underwent cryoablation of 320 primary or metastatic bone tumors be

190 c resonance (MR) imaging-guided percutaneous cryoablation of 65 liver tumors (62 metastases, three he

191 cancer that CTLA-4 blockade cooperates with cryoablation of a primary tumor to prevent the outgrowth

192 ctable melanoma progressing on ICI underwent cryoablation of an enlarging metastasis, and ICI was con

193 Cryoablation of both ventricular chambers eliminated Pur

194 Catheter cryoablation of common atrial flutter causes much less p

195 g-term outcomes of image-guided percutaneous cryoablation of cT1 RCC and to compare outcomes for CT v

196 Conclusion Percutaneous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma had similar exc

197 Cryoablation of either blood-perfused or saline-perfused

198 Cryoablation of extrinsic sympathovagal nerves eliminate

199 Cryoablation of human HER2(+) D2F2/E2 tumor enabled the

200 Following percutaneous cryoablation of liver tumors, alterations in liver enzym

201 Cryoablation of metastatic bone tumors provided rapid an

202 Cryoablation of neu(+) TUBO tumor in BALB/c mice resulte

203 dy analyzed data from patients who underwent cryoablation of peripheral lung tumors combined with air

204 ntercostal nerves from thermal injury during cryoablation of peripheral lung tumors.

205 rmal injury during image-guided percutaneous cryoablation of peripheral lung tumors.

206 MR imaging-guided focal cryoablation of recurrent prostate cancer after radiatio

207 sent the results of the first experiences in cryoablation of renal cell carcinoma in Poland.

208 ds of patients who underwent RF ablation and cryoablation of renal tumors from June 19, 2003, to Febr

209 Cryoablation of renal tumors with ultrasound monitoring

210 Image-guided percutaneous cryoablation of small (< or = 4-cm) renal lesions appear

211 Currently, cryoablation of small renal lesions is minimally invasiv

212 Cryoablation of small renal masses represents an alterna

213 AT undergoing Fontan revision are compared: cryoablation of the inferomedial right atrium (RA), and

214 ons in 0.5 to 2 mm thick tissues relevant to cryoablation of the pulmonary vein (PV).

215 ssue tissue thermocouples profiles during 53 cryoablations of 40 PVs were analyzed.

216 To evaluate the impact of adjunctive partial cryoablation on checkpoint inhibitor (CPI) immunotherapy

217 Two complications occurred in a total of 27 cryoablations: one hemorrhage, which required a blood tr

218 Because cryoablation only delayed but did not prevent sustained

219 r ventricular tachycardia underwent catheter cryoablation or radiofrequency ablation.

220 Sprague-Dawley rats underwent 35% hepatic cryoablation or RFA and were killed at 1, 2, and 6 hours

221 ], 3.1 [95% CI: 3, 7.6]; P = .01), long-bone cryoablation (OR, 17.8 [95% CI: 2.3, 136.3]; P = .01), a

222 epicardial window (Epi-window), or surgical cryoablation (OR-Cryo; age, 62+/-11 years; VT storm in 5

223 nd metastatic progression also seem to favor cryoablation over radio frequency ablation (4.6 vs. 11.7

224 own pathology for SRMs undergoing RFA versus cryoablation (P < 0.0001).

225 le success rates (82% radiofrequency vs. 85% cryoablation, p = 1.0).

226 Cryoablation patients had significantly improved symptom

227 Adrenal cryoablation patients who were not premedicated with an

228 .01) when compared with the cohort of kidney cryoablation patients.

229 Background Percutaneous cryoablation (PCA) is an increasingly utilized treatment

230 Cryoablation performed laparoscopically or percutaneousl

231 In clear cell, cryoablation plus tremelimumab leads to a significant in

232 uster (24.03 cm3), followed by those for the cryoablation probe (17.46 cm3) and single RF electrode (

233 and 3.98 cm, respectively), followed by the cryoablation probe (2.38 and 3.94 cm) and single RF elec

234 l as between the single RF electrode and the cryoablation probe (P < .001).

235 or with the RF electrode cluster versus the cryoablation probe (P = .381).

236 electrode (9.05 cm3) (single RF electrode vs cryoablation probe, P < .05).

237 ngle RF electrode, RF electrode cluster, and cryoablation probe, respectively.

238 Effectiveness of the cryoablation procedure versus drug therapy was determine

239 systolic blood pressure increase during the cryoablation procedure when compared with their counterp

240 the epicardial surface using an endocardial cryoablation procedure, and a 12-mm barrier with a 1.5-m

241 s during the final, active thaw phase of the cryoablation procedure, and one patient developed hypert

242 which was successfully treated with a second cryoablation procedure.

243 2.6 cm) in 23 patients were treated with 27 cryoablation procedures by using a protocol approved by

244 ring system was then applied to all 73 renal cryoablation procedures performed during 2012.

245 All 398 renal cryoablation procedures performed from 2003 through 2011

246 Thirty-eight (95%) of 40 cryoablation procedures were technically successful.

247 Cryoablation produced acute isolation of three or more P

248 The percutaneous cryoablation programme at Wroclaw Medical University Hos

249 Immune analysis suggests cryoablation promotes a vigorous immune response within

250 nephrectomy and ablative procedures such as cryoablation, radiofrequency ablation, and recently radi

251 d SCID mice when CpG was incorporated in the cryoablation regimen, showing significant local control

252 The patient who underwent cryoablation remains free of arrhythmias.

253 In adult hearts, cryoablation resulted in c-kit-EGFP(+) expression, peaki

254 7 rabbits after left ventricular endocardial cryoablation, resulting in a thin layer of surviving epi

255 Currently available data suggest that cryoablation results in lower retreatments (P < 0.0001),

256 lation targets while identifying sites where cryoablation should be avoided.

257 Histologic lung sections after cryoablation showed multiple foci of perivenular inflamm

258 Conclusion Adjunctive cryoablation significantly increased the response to dua

259 The loss of electrical activity within the cryoablation site exhibited a close spatial correlation

260 n (1.2% [four of 320]; mean delay, 71 days); cryoablation site infection, tumor seeding, bleeding, an

261 ng carcinoma cells were detected in the post-cryoablation surgical specimen in 19 patients; a focus o

262 Tabletop argon gas-based cryoablation system with a double-freeze-thaw protocol w

263 performed more often for lesions treated by cryoablation than RFA with a significantly higher rate o

264 Before cryoablation, the mean score for worst pain in a 24-hour

265 These data suggest that peripheral retinal cryoablation therapy is an effective treatment for activ

266 After cryoablation, there was increased echogenicity at US and

267 Skeletal injuries were coupled with cryoablation to create non-healing osteonecrotic defects

268 Since 2019 we have used cryoablation to treat 7 benign and 9 malignant lesions w

269 covery of CMAP amplitude after discontinuing cryoablation took <60 seconds in all cases.

270 Electron microscopy of cryoablation-treated liver tissue demonstrated disruptio

271 days following treatment, CPI and adjunctive cryoablation-treated MC-38 mice had a significantly incr

272 ngle renal tumor, underwent one percutaneous cryoablation treatment session that combined ultrasonogr

273 Twenty dogs underwent cryoablation using 28-mm cryoballoon, 6 dogs were done u

274 Cryoablation using this flexible argon-based device for

275 tokine levels were significantly elevated in cryoablation versus RFA animals.

276 sided and posteroseptal versus left sided), cryoablation (versus radiofrequency), empirical ablation

277 Cryoablation was associated with a significantly lower d

278 Cryoablation was associated with higher success rates an

279 30% decrease in CMAP amplitude occurred and cryoablation was discontinued.

280 on, the 30% reduction cutoff was reached and cryoablation was discontinued.

281 Hepatic cryoablation was performed in 12 rabbits with VX2 tumors

282 Cryoablation was performed in 2 patients, and radiofrequ

283 Surgical right ventricular outflow tract cryoablation was performed in 22 patients (10.7%).

284 Cryoablation was performed in 26 patients with a signifi

285 Surgical cryoablation was performed in 3 patients and abolished V

286 Cryoablation was performed with a system using argon gas

287 Cryoablation was terminated on any perceived reduction i

288 Mean (MC)2 risk score for all renal cryoablations was 4.7 (standard deviation, 1.9; range, 2

289 nd 86% (75-94; I(2)=66%) at 5 years; and for cryoablation were 95% (93-96; I(2)=61%) at 1 year, 94% (

290 mammography and US before, during, and after cryoablation were assessed to categorize densities and m

291 m colorectal cancer amenable to resection or cryoablation were eligible.

292 who underwent kidney (not in the upper pole) cryoablation (Wilcoxon rank sum test).

293 gy evolves it is likely that the efficacy of cryoablation will improve and the list of arrhythmias th

294 , 0.6-6.5 cm; median size, 2.5 cm) underwent cryoablation with CT (n = 155) or MRI (n = 152) guidance

295 Incomplete cryoablation with MMP inhibition (n = 6) versus without

296 Purpose To evaluate the effect of incomplete cryoablation with or without MMP inhibition on the local

297 /neu humoral and cellular immunity following cryoablation with or without peritumoral CpG injection w

298 Percutaneous cryoablation with US guidance and CT monitoring is safe

299 Conclusion Percutaneous cryoablation yielded a 10-year disease-specific survival

300 Cryoablation yields better cosmetic results than surgery